International Business News - Vertex http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Biotechnology company Vertex Pharmaceuticals Inc. said Monday its third-quarter loss widened as revenue fell and costs rose. The Cambridge, Mass.-based maker of drugs to combat viral diseases reported a loss of $130 million, or 93 cents per share, after posting a loss of $107 million, or 82 cents per share, in the year-ago period. http://www.ibtimes.com/articles/20081027/vertex-3q-loss-widens-as-revenue-drop-23-percent.htm Mon, 27 Oct 2008 18:02:10 EDT Shares of Vertex Pharmaceuticals Inc. rose Wednesday after the biotechnology company provided details that reaffirmed prior positive study results for its hepatitis C drug candidate telaprevir. http://www.ibtimes.com/articles/20080924/vertex-shares-rise-on-hepatitis-c-drug-detail.htm Wed, 24 Sep 2008 17:44:20 EDT Drug maker Vertex Pharmaceuticals Inc. said Monday it expanded its stock sale, as its underwriter bought 1.1 million shares for $28.7 million. The option takes Vertex's total proceeds to $220 million, as the company has sold approximately 8.6 million shares at $25.50. On Thursday, Vertex said it would sell 7.5 million shares for $191.3 million. The underwriter was not named. http://www.ibtimes.com/articles/20080922/vertex-pharma-will-expand-stock-sale.htm Mon, 22 Sep 2008 10:38:46 EDT Shares of Vertex Pharmaceuticals Inc. rose Thursday after the drug maker said it will sell 7.5 million shares of new stock to raise cash. The Cambridge, Mass., company said late Wednesday that it would sell the stock, and early Thursday it priced the offering at $25.50 per share, which would allow it to raise $191.3 million. Vertex said it will use the funds to develop its late stage drug candidates for hepatitis C and cystic fibrosis, as well as for general corporate purposes. http://www.ibtimes.com/articles/20080918/vertex-declines-after-announcing-stock-sale.htm Thu, 18 Sep 2008 19:18:16 EDT Vertex Pharmaceuticals Inc. on Thursday priced its public offering of 7.5 million common shares at $25.50 each, for expected proceeds of $191.3 million. http://www.ibtimes.com/articles/20080918/vertex-pharmaceuticals-prices-offering-at-discount.htm Thu, 18 Sep 2008 09:49:29 EDT An Oppenheimer analyst downgraded Vertex Pharmaceuticals Inc. Wednesday, saying the stock should trade around its current levels because the company won't have any significant clinical trial data to report. http://www.ibtimes.com/articles/20080903/ahead-of-the-bell-vertex-downgraded.htm Wed, 03 Sep 2008 09:27:28 EDT Shares of Vertex Pharmaceuticals Inc. fell Monday after Schering-Plough Corp. reported positive data from a trial of a hepatitis C drug, showing it could be a strong competitor to Vertex's candidate telaprevir. http://www.ibtimes.com/articles/20080804/vertex-falls-on-data-for-schering-hepatitis-drug.htm Mon, 04 Aug 2008 18:52:21 EDT Vertex Pharmaceuticals Inc. said late Thursday its hepatitis C drug candidate telaprevir was both safe and prompted a response in patients during a midstage study. http://www.ibtimes.com/articles/20080801/vertex-hepatitis-c-drug-meets-study-goal.htm Fri, 01 Aug 2008 09:20:01 EDT Vertex Pharmaceuticals Inc. said late Thursday its second-quarter loss narrowed on a large milestone payment for development of its hepatitis C drug candidate telaprevir. http://www.ibtimes.com/articles/20080801/vertex-narrows-2q-loss-but-misses-forecast.htm Fri, 01 Aug 2008 08:36:09 EDT Shares of Vertex Pharmaceuticals rose Monday as the company released data showing the company's hepatitis C drug telaprevir worked on patients who had failed a common drug regimen. http://www.ibtimes.com/articles/20080609/last-call-vertex-shares-rise-on-hepatitis-c-drug-data.htm Mon, 09 Jun 2008 16:05:00 EDT Vertex Pharmaceuticals Inc. said Monday patients who previously failed on a common hepatitis C drug regimen responded when the company's telaprevir was added to their regimen. http://www.ibtimes.com/articles/20080609/vertex-hepatitis-c-drug-shows-patient-benefit.htm Mon, 09 Jun 2008 10:42:26 EDT Vertex Pharmaceuticals Inc. shares jumped Thursday after an analyst predicted strong results and earlier approval of its hepatitis C drug candidate telaprevir. http://www.ibtimes.com/articles/20080605/vertex-rises-on-analyst-look-at-telaprevir-data.htm Thu, 05 Jun 2008 17:46:18 EDT Vertex Pharmaceuticals Inc. said Tuesday that it sold the rights to its royalty stream from two HIV drugs sold by GlaxoSmithKline PLC for $160 million. http://www.ibtimes.com/articles/20080603/vertex-sells-hiv-royalty-stream-for-160-million.htm Tue, 03 Jun 2008 10:46:28 EDT Shares of Vertex Pharmaceuticals Inc. recovered somewhat Thursday, as several analysts said the company's developing hepatitis C drug telaprevir has the potential to top rival Schering-Plough's experimental treatment. http://www.ibtimes.com/articles/20080522/analysts-say-vertex-hepatitis-c-drug-competitive.htm Thu, 22 May 2008 18:54:44 EDT Shares of Vertex Pharmaceuticals Inc. fell Wednesday after Schering-Plough Corp. said it is starting late-stage clinical testing of boceprevir, a hepatitis C drug candidate and a rival to Vertex's drug telaprevir. http://www.ibtimes.com/articles/20080521/vertex-drops-as-rivals-hepatitis-drug-advances.htm Wed, 21 May 2008 16:41:09 EDT